AUA2024: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems

CME Available: https://auau.auanet.org/node/41097

At the conclusion of this activity, participants will be able to:
1. Implement current practice guidelines and explain methods and resources to improve TURBT skills.
2. Identify the best intravesical agent and duration of therapy for low-, intermediate- and high-risk NMIBC and what to do during a BCG shortage.
3. Identify methods to treat significant toxicities from various intravesical therapies.
4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease.
5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs.

ACKNOWLEDGEMENTS
This educational activity is supported by independent educational grants from:
Merck & Co., Inc.